Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study

Prasugrel is converted into prasugrel active metabolite (PAM; R-138727) through the cytochrome P450-mediated conversion of an intermediate metabolite (PIM; R-95913). It is unknown whether PIM exerts any biological function. The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus...

Full description

Saved in:
Bibliographic Details
Published in:Arteriosclerosis, thrombosis, and vascular biology Vol. 45; no. 5; p. 792
Main Authors: Minuz, Pietro, Giorgetti, Alejandro, Meneguzzi, Alessandra, Taus, Francesco, Ribeiro, Rui P, Baldessari, Filippo, Gargiulo, Giuseppe, Gragnano, Felice, Landi, Antonio, Castelli, Marco, Gottardo, Rossella, Bortolotti, Federica, Verlato, Giuseppe, Fava, Cristiano, Cattaneo, Marco, Tagliaro, Franco, Valgimigli, Marco
Format: Journal Article
Language:English
Published: United States 01.05.2025
Subjects:
ISSN:1524-4636, 1524-4636
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first